angiotensin ii has been researched along with ecallantide in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Campbell, DJ; Dixon, B; Kemme, M; Kladis, A; Santamaria, JD | 1 |
| Klahr, S; Morrissey, J | 1 |
| Chen, T; Chen, W; Feng, H; Guo, C; Jia, Z; Li, C; Li, M; Liu, X; Shi, J; Tang, X; Wang, J; Xia, M; Yin, Y | 1 |
1 review(s) available for angiotensin ii and ecallantide
| Article | Year |
|---|---|
Comparative effects of ACE inhibition and angiotensin II receptor blockade in the prevention of renal damage.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Diabetic Nephropathies; Disease Progression; Humans; Kidney Failure, Chronic; Nephritis, Interstitial; Plasma Kallikrein; Renin-Angiotensin System | 2002 |
2 other study(ies) available for angiotensin ii and ecallantide
| Article | Year |
|---|---|
Activation of the kallikrein-kinin system by cardiopulmonary bypass in humans.
Topics: Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Arteries; Blood Proteins; Bradykinin; Cardiopulmonary Bypass; Carrier Proteins; Enzyme Activation; Heart Diseases; Humans; Kallidin; Kininogens; Kinins; Plasma Kallikrein; Serpins; Tissue Kallikreins; Veins | 2001 |
Inhibition of plasma kallikrein mitigates experimental hypertension-enhanced cerebral hematoma expansion.
Topics: Angiotensin II; Animals; Blood Pressure; Cerebral Hemorrhage; Crotalid Venoms; Disease Models, Animal; Hypertension; Lectins, C-Type; Male; Mice; Plasma Kallikrein; Treatment Outcome | 2021 |